Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selenium in Mild-to-Moderate Graves' Ophthalmopathy
NCT06413043Not yet recruiting
- Sponsor
- AIIMS New Delhi
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial in Graves' ophthalmopathy (TED) comparing ADD on Selenium with Placebo (2 arms). Primary endpoint: Response of add on selenium in patients with grave's ophthalmopathy at 90 days. Planned start May 2024; status: not yet recruiting.
02
Drugs
selenium
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT06413043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413043.